Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1209

1.

Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.

Varker KA, Kondadasula SV, Go MR, Lesinski GB, Ghosh-Berkebile R, Lehman A, Monk JP, Olencki T, Kendra K, Carson WE 3rd.

Clin Cancer Res. 2006 Oct 1;12(19):5850-8.

PMID:
17020993
[PubMed - indexed for MEDLINE]
Free Article
2.

Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy.

Lesinski GB, Kondadasula SV, Crespin T, Shen L, Kendra K, Walker M, Carson WE 3rd.

J Natl Cancer Inst. 2004 Sep 1;96(17):1331-42.

PMID:
15339971
[PubMed - indexed for MEDLINE]
Free Article
3.

Impaired STAT phosphorylation in T cells from melanoma patients in response to IL-2: association with clinical stage.

Mortarini R, Vegetti C, Molla A, Arienti F, Ravagnani F, Maurichi A, Patuzzo R, Santinami M, Anichini A.

Clin Cancer Res. 2009 Jun 15;15(12):4085-94. doi: 10.1158/1078-0432.CCR-08-3323. Epub 2009 Jun 9.

PMID:
19509154
[PubMed - indexed for MEDLINE]
Free Article
4.

Activation of extracellular signaling regulated kinase in natural killer cells and monocytes following IL-2 stimulation in vitro and in patients undergoing IL-2 immunotherapy: analysis via dual parameter flow-cytometric assay.

Kondadasula SV, Varker KA, Lesinski GB, Benson DM Jr, Lehman A, Olencki T, Monk JP, Kendra K, Carson WE 3rd.

Cancer Immunol Immunother. 2008 Aug;57(8):1137-49. doi: 10.1007/s00262-007-0444-7. Epub 2008 Jan 10.

PMID:
18193422
[PubMed - indexed for MEDLINE]
5.

Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma.

Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S, Kaufman HL.

J Clin Oncol. 2006 Mar 1;24(7):1169-77.

PMID:
16505437
[PubMed - indexed for MEDLINE]
6.

Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer.

van der Vliet HJ, Koon HB, Yue SC, Uzunparmak B, Seery V, Gavin MA, Rudensky AY, Atkins MB, Balk SP, Exley MA.

Clin Cancer Res. 2007 Apr 1;13(7):2100-8. Erratum in: Clin Cancer Res. 2007 Jun 1;13(11):3433. van der Vliet, Hans J J [corrected to van der Vliet, Hans J].

PMID:
17404092
[PubMed - indexed for MEDLINE]
Free Article
7.

IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma.

Frederiksen KS, Lundsgaard D, Freeman JA, Hughes SD, Holm TL, Skrumsager BK, Petri A, Hansen LT, McArthur GA, Davis ID, Skak K.

Cancer Immunol Immunother. 2008 Oct;57(10):1439-49. doi: 10.1007/s00262-008-0479-4. Epub 2008 Feb 20.

PMID:
18286285
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Transcription factor activation in lymphokine activated killer cells and lymphocytes from patients receiving IL-2 immunotherapy.

Nicolet CM, Surfus JM, Hank JA, Sondel PM.

Cancer Immunol Immunother. 1998 Aug;46(6):327-37.

PMID:
9756417
[PubMed - indexed for MEDLINE]
9.

Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma.

Maxwell W, McDevitt J, Reid I, Sharpe I, Feighery C, Tanner WA, Emmons R, Monson JR.

Eur J Surg Oncol. 1993 Jun;19(3):265-72.

PMID:
8314385
[PubMed - indexed for MEDLINE]
10.

Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.

de Gast GC, Klümpen HJ, Vyth-Dreese FA, Kersten MJ, Verra NC, Sein J, Batchelor D, Nooijen WJ, Schornagel JH.

Clin Cancer Res. 2000 Apr;6(4):1267-72.

PMID:
10778950
[PubMed - indexed for MEDLINE]
Free Article
11.

Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.

Belldegrun A, Tso CL, Kaboo R, Pang S, Pierce W, deKernion JB, Figlin R.

J Immunother Emphasis Tumor Immunol. 1996 Mar;19(2):149-61.

PMID:
8732698
[PubMed - indexed for MEDLINE]
12.

Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells.

Lesinski GB, Trefry J, Brasdovich M, Kondadasula SV, Sackey K, Zimmerer JM, Chaudhury AR, Yu L, Zhang X, Crespin TR, Walker MJ, Carson WE 3rd.

Clin Cancer Res. 2007 Sep 1;13(17):5010-9.

PMID:
17785551
[PubMed - indexed for MEDLINE]
Free Article
13.

Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma.

Aklilu M, Stadler WM, Markiewicz M, Vogelzang NJ, Mahowald M, Johnson M, Gajewski TF.

Ann Oncol. 2004 Jul;15(7):1109-14.

PMID:
15205206
[PubMed - indexed for MEDLINE]
Free Article
14.

Defective interleukin-2-dependent STAT5 signalling in CD8 T lymphocytes from HIV-positive patients: restoration by antiretroviral therapy.

Kryworuchko M, Pasquier V, Keller H, David D, Goujard C, Gilquin J, Viard JP, Joussemet M, Delfraissy JF, Thèze J.

AIDS. 2004 Feb 20;18(3):421-6.

PMID:
15090793
[PubMed - indexed for MEDLINE]
15.

Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104).

Asemissen AM, Scheibenbogen C, Letsch A, Hellstrand K, Thorén F, Gehlsen K, Schmittel A, Thiel E, Keilholz U.

Clin Cancer Res. 2005 Jan 1;11(1):290-7.

PMID:
15671558
[PubMed - indexed for MEDLINE]
Free Article
16.

Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study.

Westermann J, Reich G, Kopp J, Haus U, Dörken B, Pezzutto A.

Cancer Immunol Immunother. 2001 Jan;49(11):613-20.

PMID:
11225992
[PubMed - indexed for MEDLINE]
17.

A potential role for hydrocortisone in the positive regulation of IL-15-activated NK-cell proliferation and survival.

Perez SA, Mahaira LG, Demirtzoglou FJ, Sotiropoulou PA, Ioannidis P, Iliopoulou EG, Gritzapis AD, Sotiriadou NN, Baxevanis CN, Papamichail M.

Blood. 2005 Jul 1;106(1):158-66. Epub 2005 Mar 8.

PMID:
15755904
[PubMed - indexed for MEDLINE]
Free Article
18.

Transforming growth factor-beta downregulates interleukin-2-induced phosphorylation of signal transducer and activator of transcription 5 in human renal cell carcinoma.

Song C, Jun SY, Hong JH, Ahn H.

J Cancer Res Clin Oncol. 2007 Jul;133(7):487-92. Epub 2007 Feb 6.

PMID:
17279417
[PubMed - indexed for MEDLINE]
19.

Discrimination of different subsets of cytolytic cells in pseudorabies virus-immune and naive pigs.

de Bruin TG, van Rooij EM, de Visser YE, Voermans JJ, Samsom JN, Kimman TG, Bianchi AT.

J Gen Virol. 2000 Jun;81(Pt 6):1529-37.

PMID:
10811936
[PubMed - indexed for MEDLINE]
Free Article
20.

Reduced numbers of IL-7 receptor (CD127) expressing immune cells and IL-7-signaling defects in peripheral blood from patients with breast cancer.

Vudattu NK, Magalhaes I, Schmidt M, Seyfert-Margolis V, Maeurer MJ.

Int J Cancer. 2007 Oct 1;121(7):1512-9.

PMID:
17546596
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk